FDA-approved as the first and only approved first line treatment for advanced squamous cell carcinoma of the anal canal.

Recently approved medications for resistant hypertension, uncomplicated UTIs and menopausal hot flashes show potential as ...

The FDA approved retifanlimab (Zynyz; Incyte) as the first and only first-line treatment for advanced anal cancer, supported ...

The FDA has approved Allecra Therapeutics' Exblifep, a combination antibiotic for complicated urinary tract infections (cUTIs ... for the treatment of cUTIs in adults, including severe kidney ...

With significant survival improvements seen, the FDA has granted approval to retifanlimab for the first-line treatment of ...

The FDA has approved Zynyz (retifanlimab-dlwr) to treat patients with squamous cell carcinoma of the anal canal.

and urinary tract infections. According to the company’s safety information, doctors must advise their patients about using effective contraception during the therapy as the new treatment can ...

Zynyz is the first and only FDA-approved first-line treatment for adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal.

Focusing on a new antibiotic for UTIs, which haven’t had a novel therapy in decades, was intentional, Walmsley says. Half of ...

Treatment with the Avmapki Fakzynja Co-pack received accelerated FDA approval for previously treated low-grade serous ovarian ...

The FDA has granted accelerated approval to avutometinib (VS-6766) plus defactinib (VS-6063) for the treatment of adult ...